A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2019
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 Sep 2018 Planned number of patients changed from 750 to 669.
- 04 Sep 2018 Planned End Date changed from 17 May 2021 to 27 May 2021.
- 04 Sep 2018 Planned primary completion date changed from 17 May 2021 to 27 May 2021.